Genoray

Founded in 2001 and listed on KOSDAQ in 2018, Genoray is a medical X-ray imaging device specialist and the only Korean company that simultaneously operates both a medical segment (C-arm, mammography) and a dental segment (panorama, CT, portable X-ray).

The company has said it held the No.1 cumulative domestic market share in three core product lines—C-arm, mammography, and ENT (ear-nose-throat) CT—based on full-year 2025 results. Genoray has internalized core components such as X-ray generators and CMOS FPD sensors, securing both cost competitiveness and quality.

On the global network side, the company operates five overseas subsidiaries in the United States, Germany, Japan, Turkey, and China with over 150 partner companies, exporting to more than 80 countries, with roughly 75% of total revenue generated overseas.

More recently, Genoray has expanded ODM exports to Japan through a strategic partnership with GC Corporation, leveraging GC's local sales network, while in China it has signed dental CT supply and technology-cooperation agreements with HMD, Shanghai Electric, and the Colorful Group.

Listed domestic peers in dental imaging include Vatech, Ray, and Vieworks, while the medical segment competes with separate specialists in C-arm and mammography equipment.

The company invests roughly 8-10% of revenue annually in R&D, focusing on low-dose, high-resolution imaging and AI deep-learning-based automated diagnostics.

Consolidated 2025 revenue came to KRW 108.04 billion, a modest increase from KRW 106.98 billion in 2024, but operating profit turned negative at KRW -243 million, reversing from KRW 6.51 billion (a 6.1% operating margin) the prior year.

Net income attributable to owners nonetheless stayed marginally positive at KRW 758 million, an improvement from a net loss of KRW 1.80 billion in 2024.

Compared with double-digit operating margins in 2022 (18.1% on revenue of KRW 82.60 billion) and 2023 (13.0% on revenue of KRW 97.90 billion), the profitability decline of the past two years stands out.

Quarterly figures show even more pronounced swings: third-quarter 2025 revenue was KRW 21.83 billion with an operating loss of KRW 1.66 billion and a net loss of KRW 998 million, while fourth-quarter 2025 revenue jumped to KRW 34.05 billion with operating profit of KRW 1.38 billion and net income of KRW 3.40 billion—a figure notably larger than the operating profit itself.

First-quarter 2026 reverted to losses, with revenue of KRW 25.39 billion, an operating loss of KRW 1.58 billion, and a net loss of KRW 407 million, before second-quarter 2026 swung back to profit with revenue of KRW 26.62 billion, operating profit of KRW 249 million, and net income of KRW 606 million.

The gap between operating and net income, especially in the fourth quarter of 2025, suggests non-operating items had a meaningful effect on quarterly results.

Operating cash flow also fluctuated more than earnings, at KRW 14.84 billion in 2022, KRW 3.55 billion in 2023, KRW 13.27 billion in 2024, and KRW 5.26 billion in 2025.

The dental and medical imaging device industry is generally cited as having long-term growth drivers tied to rising diagnostic and procedural demand from an aging population and expanding healthcare infrastructure in emerging markets.

According to the company, C-arm demand tied to an aging population has stayed resilient, while dental CT demand has been more volatile, weighing on recent results.

Some assessments suggest the domestic market's growth is limited given already-high equipment penetration, while overseas government-tender markets (such as Turkey) and partner-driven ODM and distribution expansion (Japan's GC, China's HMD and Shanghai Electric) serve as growth channels.

Among listed domestic dental imaging peers, Vatech is the largest by scale, with Vieworks and Ray operating similar businesses. Larger global dental device makers include Henry Schein and Dentsply Sirona.

Within the industry, the pace of securing new-product certifications in markets such as China, Europe, and the United States is considered a key variable for revenue expansion. Expansion into adjacent markets, such as veterinary imaging devices, has also emerged as one of several industry-wide growth strategies.

The company has stated that its new dental CBCT product, the GT300, received certification from Korea's Ministry of Food and Drug Safety and was launched domestically, with plans to expand overseas sales through additional certifications in China, Europe, and the United States.

On business expansion, the company previously announced plans to enter the veterinary imaging market with its VETERA veterinary X-ray device targeting veterinarians and animal hospitals.

Overseas, Genoray disclosed that it secured a mammography tender win with its HESTIA product from Turkey's Ministry of Health, and separately announced an ODM agreement with Japan's Shimadzu Corporation to supply Mobile C-Arm units at scale.

In an April 2025 report, the Korea Investors Relations Service projected that new product launches and entry into the veterinary imaging market in the second half would sustain domestic revenue growth, without providing an investment rating or target price.

The company also said it is developing a dental CAD/CAM-integrated software business. Whether these new-product and new-market initiatives can meaningfully reduce the recent quarterly earnings volatility remains something to be confirmed through upcoming quarterly disclosures.